Millennium Biotechnologies Group Announces Their Resurgex Line of Products are Successfully Launched and Distributed in Greece

Nutrimedica Successfully Launches the Resurgex Line Into Hospitals, Pharmacies, and Direct to Patients in Greece


BASKING RIDGE, N.J. , April 4, 2007 (PRIME NEWSWIRE) -- Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTCBB:MBTG) reports a successful international distribution partnership for the Resurgex(r) line of products in Greece. This accomplishment for the Resurgex product line comes on the heels of announcing a distribution and marketing initiative for the Canadian marketplace,. A successful entry of a U.S. product into the Greek market depends on proper selection of a qualified distributor in Greece, which is knowledgeable of the local market and regulations. The distributor must be capable of developing a proper relationship with the distribution chain of medical institutions, practitioners and proper retail outlets in the medical marketplace. Millennium has chosen Nutrimedica, a well known distributor of nutritional products, in Athens. It has already imported and distributed Resurgex(r) products to hospitals, pharmacies, and direct to patients. Nutrimedica reports that the introduction of Resurgex products has been well received and sales have been steadily increasing over the last year.

"We are very pleased with Nutrimedica's initial distribution and sales success of Resurgex(r) products in Greece. Coupled with our recent Resurgex(r) distribution agreement with a pharmaceutical company in Canada, we look forward to opportunities in other international markets as well," said Jerry Swon, CEO of MBTG. "In the past year, the total Greek market for nutritional products topped over $35 million, and is anticipated to increase at an annual rate of approximately 30% per year for the next five years as a result of the Government's announcement of a new policy on the overall pharmaceutical sector and further European harmonization. This should allow for a healthy growth rate for the Resurgex(r) line of products in Greece and a successful platform for further expansion throughout Europe and Asia."

About Millennium Biotechnologies, Inc.:

Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, Resurgex(r), Resurgex Plus(r), and Resurgex Select(r), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions.

Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTCBB:MBTG). For more information about Millennium Biotechnologies, please contact Jerry Swon, Chief Executive Officer, at jswon@milbiotech.com or call (908) 604-2500. For more information about the Resurgex line of products visit www.resurgex.com.

This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and Resurgex Plus and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially form those anticipated in such forward-looking statements even if experience or future changes make it clear the any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.



            

Contact Data